•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.SCI Engineered Materials, Inc. Announces Management Transition
Baillie Gifford Trims Service Corp International (SCI) Stake by 35.5%
SCI Engineered Materials, Inc. Announces Installation of Plasma Spheroidization System
SERVICE CORPORATION INTERNATIONAL DECLARES QUARTERLY CASH DIVIDEND
Service Corporation International Q2 Earnings Call Highlights
Service Corporation International (SCI) Q2 2026 Earnings Call Transcript
Service Corporation Q2 Earnings Beat Estimates, Revenues Rise 4% Y/Y
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
SCI Engineered Materials, Inc. Reports 2026 Second Quarter and Six-Month Results
Service Corp. (SCI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Service Corp. (SCI) Beats Q2 Earnings and Revenue Estimates
SERVICE CORPORATION INTERNATIONAL ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS, CONFIRMS 2026 EARNINGS PER SHARE MIDPOINT GUIDANCE, AND RAISES 2026 CASH FLOW GUIDANCE
Service Corp International (SCI) Stock Up 3.8% and Still Undervalued -- GF Score: 83/100
Service Corporation Q2 Earnings on Deck: Factors to Watch for SCI
Service Corporation International Announces Schedule For Second Quarter 2026 Earnings Release and Conference Call
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
CEL-SCI Announces Closing of Offering
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
CEL-SCI Corporation Announces Pricing of Offering